| Q22241393 | 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. |
| Q35570030 | A benefit-risk assessment of sibutramine in the management of obesity |
| Q42711225 | American College of Endocrinology Pre-Diabetes Consensus Conference: part two. |
| Q46548666 | An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. |
| Q35147057 | Current management strategies for coexisting diabetes mellitus and obesity |
| Q37368688 | Current pharmacotherapeutic concepts for the treatment of obesity in adults |
| Q46824240 | Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers |
| Q84550793 | Drug treatment for obesity in the post-sibutramine era |
| Q30359088 | Drug treatments for obesity: orlistat, sibutramine, and rimonabant. |
| Q38729150 | Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. |
| Q42657204 | Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study |
| Q39130400 | Factors involved in white-to-brown adipose tissue conversion and in thermogenesis: a review |
| Q46220789 | Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery |
| Q36652836 | Insulin treatment and the problem of weight gain in type 2 diabetes |
| Q24200212 | Long-term effects of weight-reducing drugs in hypertensive patients |
| Q24239850 | Long-term effects of weight-reducing drugs in hypertensive patients |
| Q24186054 | Long-term effects of weight-reducing drugs in people with hypertension |
| Q24247723 | Long-term pharmacotherapy for obesity and overweight |
| Q37393606 | Magnitude of type 1 diabetes self-management in youth: health care needs diabetes educators |
| Q37750274 | Managing type 2 diabetes: balancing HbA1c and body weight |
| Q37679879 | Modern management of obesity. |
| Q35219421 | Nutrition therapy for hypertension |
| Q35623051 | Obesity and pharmacologic therapy |
| Q35623015 | Obesity and type 2 diabetes |
| Q61775731 | Obesity in Older Adults: Technical Review and Position Statement of the American Society for Nutrition and NAASO, The Obesity Society |
| Q36216869 | Optimal diabetes management during medical weight loss for cardiovascular risk reduction |
| Q24245173 | Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus |
| Q34572487 | Present and future: pharmacologic treatment of obesity |
| Q24658031 | Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders |
| Q34026742 | Rise and fall of anti-obesity drugs |
| Q92391641 | SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice |
| Q34016243 | Safety of antiobesity drugs |
| Q35496591 | Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis |
| Q28282364 | Serotonergic drugs : effects on appetite expression and use for the treatment of obesity |
| Q35688185 | Sibutramine and the management of obesity |
| Q48021282 | Sibutramine promotes amygdala activity under fasting conditions in obese women |
| Q36183802 | Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice |
| Q30401145 | Tackling obesity: new therapeutic agents for assisted weight loss. |
| Q39550978 | Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons |
| Q37812687 | The Evidence for Medical Nutrition Therapy for Type 1 and Type 2 Diabetes in Adults |
| Q36098218 | The evolution of the nutritional management of diabetes |
| Q37494318 | The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions |
| Q37202159 | The use of sibutramine in the management of obesity and related disorders: an update |
| Q36815978 | Treating the metabolic syndrome. |
| Q51387052 | Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. |
| Q34159414 | Weight Considerations in Pharmacotherapy for Type 2 Diabetes |
| Q34982478 | Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). |
| Q39942800 | What is the best treatment for prediabetes? |